Lipocine Inc. (LPCN) Expected to Announce Earnings of -$0.27 Per Share

Analysts expect that Lipocine Inc. (NASDAQ:LPCN) will post ($0.27) earnings per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Lipocine’s earnings, with the highest EPS estimate coming in at ($0.23) and the lowest estimate coming in at ($0.30). Lipocine reported earnings per share of ($0.16) during the same quarter last year, which would suggest a negative year-over-year growth rate of 68.8%. The firm is scheduled to report its next quarterly earnings results on Monday, March 5th.

On average, analysts expect that Lipocine will report full-year earnings of ($1.06) per share for the current fiscal year, with EPS estimates ranging from ($1.11) to ($1.01). For the next financial year, analysts expect that the company will post earnings of ($0.40) per share, with EPS estimates ranging from ($0.97) to $0.25. Zacks Investment Research’s earnings per share calculations are an average based on a survey of research analysts that that provide coverage for Lipocine.

Several research firms have commented on LPCN. Canaccord Genuity set a $11.00 price objective on shares of Lipocine and gave the company a “buy” rating in a report on Monday, August 7th. Roth Capital set a $38.00 price objective on shares of Lipocine and gave the company a “buy” rating in a report on Thursday, August 10th. Finally, ValuEngine downgraded shares of Lipocine from a “hold” rating to a “sell” rating in a report on Thursday, August 10th.

Several institutional investors and hedge funds have recently added to or reduced their stakes in LPCN. KCG Holdings Inc. lifted its holdings in shares of Lipocine by 27.4% in the 1st quarter. KCG Holdings Inc. now owns 33,537 shares of the specialty pharmaceutical company’s stock valued at $131,000 after acquiring an additional 7,219 shares during the last quarter. LMR Partners LLP bought a new position in shares of Lipocine in the 2nd quarter valued at about $173,000. Parametric Portfolio Associates LLC lifted its holdings in shares of Lipocine by 27.1% in the 1st quarter. Parametric Portfolio Associates LLC now owns 58,739 shares of the specialty pharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,518 shares during the last quarter. Goldman Sachs Group Inc. bought a new position in shares of Lipocine in the 2nd quarter valued at about $300,000. Finally, Federated Investors Inc. PA lifted its holdings in shares of Lipocine by 9.2% in the 2nd quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock valued at $354,000 after acquiring an additional 7,429 shares during the last quarter. 22.06% of the stock is owned by institutional investors and hedge funds.

Lipocine (NASDAQ:LPCN) traded down $0.05 on Thursday, hitting $3.57. 134,507 shares of the company’s stock traded hands, compared to its average volume of 235,934. Lipocine has a twelve month low of $3.17 and a twelve month high of $5.33.

WARNING: This news story was first reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another site, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/30/lipocine-inc-lpcn-expected-to-announce-earnings-of-0-27-per-share-2.html.

Lipocine Company Profile

Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.

Get a free copy of the Zacks research report on Lipocine (LPCN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply